Roivant Sciences Ltd. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: -71.6%
EBITDA: +71.1%
EBIT: -28.1%
EPS: -87.5%
Free cash flow: +10.1%
Operating cash flow: +10.6%

Forward estimates

Revenue: +536.7%
EBITDA: +79.9%
EPS: —

Three-year CAGR

Revenue: -36.0%
EBITDA: +60.9%
EBIT: -15.4%
Net income: -74.3%
EPS: -79.2%
Free cash flow: +10.1%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.